IO Biotech Exceeds Q2 2024 EPS Expectations
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
- Latest
- Trending
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
Belarusian-Ukrainian suspect charged in US for ransomware and malvertising crimes after a 9-year global search.
Ogeechee Tech's new club boosts cybersecurity skills through training and competitions.
Cognitive technology tested in space on TES-11 to automate satellite communications without human interaction.
Discover how ChatGPT can be your ally in learning high-income skills, boosting salary, and achieving career goals effectively.
Kaspersky reports Chinese hackers using GrewApacha to infiltrate Russian systems, raising cybersecurity concerns.
The data breach at EVIT exposed sensitive information of 208,717 individuals, highlighting the need for enhanced cybersecurity.
New GhostWrite CPU bug allows attackers to access and control T-Head devices, affecting security and performance.
Cloud security expert Shai Morag now leads Tenable's product strategy, boosting innovation in cloud-first security solutions.
Researchers discover vulnerabilities in Azure's AI Health Bot, raising security concerns for sensitive data access.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.